The evolution of clostridium difficile infection in cancer patients: Epidemiology, pathophysiology, and guidelines for prevention and management

Areej Khan, Shahzad Raza, Syeda A. Batul, Monis Khan, Tulay Aksoy, Mahadi A. Baig, Barbara J. Berger

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) has emerged as a significant challenge to the healthcare system. The availability of anti-cancer chemotherapeutic regimens has contemporaneously resulted in a larger population of patients who are susceptible to CDI. The outbreak of a novel, hypervirulent, resistant strain, NAP-1/027 as well as resistance to antibiotic therapy have further contributed to an increase in prevalence as well as in disease severity. Recent data show high fatality rates in cancer patients with CDI. In this review, we have discussed the incidence, epidemiology, pathophysiology, clinical signs and symptoms and therapeutic guidelines for patients who are on chemotherapy and present with CDI and highlighted clinical reports documenting severe CDI associated with chemotherapeutic agents such as methotrexate, 5FU, cisplatin, carboplatin, paclitaxel, vinorelbine and cyclophosphamide. The review article also has the discussion of patents pertaining to infections caused by Clostridium difficile in cancer patients. We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients and for the design and implementation of randomized clinical trials of new treatment modalities in the management of chemotherapy- associated CDI.

Original languageEnglish (US)
Pages (from-to)157-170
Number of pages14
JournalRecent Patents on Anti-Infective Drug Discovery
Volume7
Issue number2
DOIs
StatePublished - 2012

Fingerprint

Clostridium Infections
Clostridium difficile
Epidemiology
Guidelines
Neoplasms
Drug Therapy
Patents
Carboplatin
Microbial Drug Resistance
Methotrexate
Fluorouracil
Cyclophosphamide
Signs and Symptoms
Disease Outbreaks
Early Diagnosis
Therapeutics
Randomized Controlled Trials
Delivery of Health Care
Incidence

Keywords

  • Anti-neoplastic chemotherapy
  • Clostridium difficile infection
  • Hypervirulent strain NAP-1/027
  • Metronidazole
  • Vancomycin

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery

Cite this

The evolution of clostridium difficile infection in cancer patients : Epidemiology, pathophysiology, and guidelines for prevention and management. / Khan, Areej; Raza, Shahzad; Batul, Syeda A.; Khan, Monis; Aksoy, Tulay; Baig, Mahadi A.; Berger, Barbara J.

In: Recent Patents on Anti-Infective Drug Discovery, Vol. 7, No. 2, 2012, p. 157-170.

Research output: Contribution to journalArticle

Khan, Areej ; Raza, Shahzad ; Batul, Syeda A. ; Khan, Monis ; Aksoy, Tulay ; Baig, Mahadi A. ; Berger, Barbara J. / The evolution of clostridium difficile infection in cancer patients : Epidemiology, pathophysiology, and guidelines for prevention and management. In: Recent Patents on Anti-Infective Drug Discovery. 2012 ; Vol. 7, No. 2. pp. 157-170.
@article{2a21b2cd43c642d4b0342d8acd286988,
title = "The evolution of clostridium difficile infection in cancer patients: Epidemiology, pathophysiology, and guidelines for prevention and management",
abstract = "Clostridium difficile infection (CDI) has emerged as a significant challenge to the healthcare system. The availability of anti-cancer chemotherapeutic regimens has contemporaneously resulted in a larger population of patients who are susceptible to CDI. The outbreak of a novel, hypervirulent, resistant strain, NAP-1/027 as well as resistance to antibiotic therapy have further contributed to an increase in prevalence as well as in disease severity. Recent data show high fatality rates in cancer patients with CDI. In this review, we have discussed the incidence, epidemiology, pathophysiology, clinical signs and symptoms and therapeutic guidelines for patients who are on chemotherapy and present with CDI and highlighted clinical reports documenting severe CDI associated with chemotherapeutic agents such as methotrexate, 5FU, cisplatin, carboplatin, paclitaxel, vinorelbine and cyclophosphamide. The review article also has the discussion of patents pertaining to infections caused by Clostridium difficile in cancer patients. We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients and for the design and implementation of randomized clinical trials of new treatment modalities in the management of chemotherapy- associated CDI.",
keywords = "Anti-neoplastic chemotherapy, Clostridium difficile infection, Hypervirulent strain NAP-1/027, Metronidazole, Vancomycin",
author = "Areej Khan and Shahzad Raza and Batul, {Syeda A.} and Monis Khan and Tulay Aksoy and Baig, {Mahadi A.} and Berger, {Barbara J.}",
year = "2012",
doi = "10.2174/157489112801619674",
language = "English (US)",
volume = "7",
pages = "157--170",
journal = "Recent Patents on Anti-Infective Drug Discovery",
issn = "1574-891X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - The evolution of clostridium difficile infection in cancer patients

T2 - Epidemiology, pathophysiology, and guidelines for prevention and management

AU - Khan, Areej

AU - Raza, Shahzad

AU - Batul, Syeda A.

AU - Khan, Monis

AU - Aksoy, Tulay

AU - Baig, Mahadi A.

AU - Berger, Barbara J.

PY - 2012

Y1 - 2012

N2 - Clostridium difficile infection (CDI) has emerged as a significant challenge to the healthcare system. The availability of anti-cancer chemotherapeutic regimens has contemporaneously resulted in a larger population of patients who are susceptible to CDI. The outbreak of a novel, hypervirulent, resistant strain, NAP-1/027 as well as resistance to antibiotic therapy have further contributed to an increase in prevalence as well as in disease severity. Recent data show high fatality rates in cancer patients with CDI. In this review, we have discussed the incidence, epidemiology, pathophysiology, clinical signs and symptoms and therapeutic guidelines for patients who are on chemotherapy and present with CDI and highlighted clinical reports documenting severe CDI associated with chemotherapeutic agents such as methotrexate, 5FU, cisplatin, carboplatin, paclitaxel, vinorelbine and cyclophosphamide. The review article also has the discussion of patents pertaining to infections caused by Clostridium difficile in cancer patients. We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients and for the design and implementation of randomized clinical trials of new treatment modalities in the management of chemotherapy- associated CDI.

AB - Clostridium difficile infection (CDI) has emerged as a significant challenge to the healthcare system. The availability of anti-cancer chemotherapeutic regimens has contemporaneously resulted in a larger population of patients who are susceptible to CDI. The outbreak of a novel, hypervirulent, resistant strain, NAP-1/027 as well as resistance to antibiotic therapy have further contributed to an increase in prevalence as well as in disease severity. Recent data show high fatality rates in cancer patients with CDI. In this review, we have discussed the incidence, epidemiology, pathophysiology, clinical signs and symptoms and therapeutic guidelines for patients who are on chemotherapy and present with CDI and highlighted clinical reports documenting severe CDI associated with chemotherapeutic agents such as methotrexate, 5FU, cisplatin, carboplatin, paclitaxel, vinorelbine and cyclophosphamide. The review article also has the discussion of patents pertaining to infections caused by Clostridium difficile in cancer patients. We underscore the urgent need for early recognition and diagnosis of CDI in cancer patients and for the design and implementation of randomized clinical trials of new treatment modalities in the management of chemotherapy- associated CDI.

KW - Anti-neoplastic chemotherapy

KW - Clostridium difficile infection

KW - Hypervirulent strain NAP-1/027

KW - Metronidazole

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84863928617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863928617&partnerID=8YFLogxK

U2 - 10.2174/157489112801619674

DO - 10.2174/157489112801619674

M3 - Article

C2 - 22792862

AN - SCOPUS:84863928617

VL - 7

SP - 157

EP - 170

JO - Recent Patents on Anti-Infective Drug Discovery

JF - Recent Patents on Anti-Infective Drug Discovery

SN - 1574-891X

IS - 2

ER -